Literature DB >> 9428623

Various hypertrophic stimuli induce distinct phenotypes in cardiomyocytes.

M C Schaub1, M A Hefti, B A Harder, H M Eppenberger.   

Abstract

Cardiac hypertrophy is characterized by an increase in cell size in the absence of cell division and is accompanied by a number of qualitative and quantitative changes in gene expression. Most forms of hypertrophy in vivo are compensatory or adaptative responses to increased workload resulting from various physiological and/or pathological etiologies. Until severe pathological alterations become apparent, myocytes show no drastic morphological changes. On the level of gene expression, upregulation of the so-called fetal genes, i.e., beta-myosin heavy chain, alpha-skeletal and alpha-smooth muscle actin, and atrial natriuretic factor (ANF) may be observed concomitant with a downregulation of alpha-myosin heavy chain and the Ca pump of sarcoplasmic reticulum. The use of primary cell culture systems for cardiomyocytes as an in vitro model for the hypertrophic reaction has identified a number of different stimuli as mediators of cardiac myocyte hypertrophy. The molecular dissection of the different intracellular signaling pathways involved herein has uncovered a number of branching points to cytosolic and nuclear targets and has identified many interactions between these pathways. The individual administration of these hypertrophic stimuli, i.e., hormones, cytokines, growth factors, vasoactive peptides, and catecholamines, to cultured cardiomyocytes, reveals that each stimulus induces a distinct phenotype as characterized by gene expression pattern and cellular morphology. Surprisingly, triiodothyronine (T3) and basic fibroblast growth factor (bFGF) effect a similar cellular phenotype although they use completely different intracellular pathways. This phenotype is characterized by drastic inhibition of myofibrillar growth and by upregulation of alpha-smooth muscle actin. On the other hand, insulin-like growth factor (IGF) I, a factor promoting muscle cell differentiation, and bFGF, an inhibitor of differentiation, cause completely different cardiomyocyte phenotypes although both are known to signal via receptor tyrosine kinases and have been shown to activate the Ras-Raf-MEK-MAP kinase pathway. However, both IGF-I and bFGF depend on T3 to bring about their typical responses, i.e., T3 is permissive for the action of these two growth factors on the expression of alpha-smooth muscle actin and cell morphology. Most of the hypertrophic stimuli are balanced under normal circumstances in vivo. When this balance is disturbed, however, a pathological heart phenotype may become dominant. Thus the knowledge of signaling pathways and cellular responses triggered by hypertrophic stimuli may be essential for the implementation of therapeutic strategies in the treatment of cardiac hypertrophy.

Entities:  

Mesh:

Year:  1997        PMID: 9428623     DOI: 10.1007/s001090050182

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  45 in total

1.  Expression profiling reveals distinct sets of genes altered during induction and regression of cardiac hypertrophy.

Authors:  C J Friddle; T Koga; E M Rubin; J Bristow
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

Review 2.  Signaling and cellular mechanisms in cardiac protection by ischemic and pharmacological preconditioning.

Authors:  Michael Zaugg; Marcus C Schaub
Journal:  J Muscle Res Cell Motil       Date:  2003       Impact factor: 2.698

Review 3.  Electrical and mechanical stimulation of cardiac cells and tissue constructs.

Authors:  Whitney L Stoppel; David L Kaplan; Lauren D Black
Journal:  Adv Drug Deliv Rev       Date:  2015-07-30       Impact factor: 15.470

Review 4.  Myofibrillar remodeling in cardiac hypertrophy, heart failure and cardiomyopathies.

Authors:  Jarmila Machackova; Judit Barta; Naranjan S Dhalla
Journal:  Can J Cardiol       Date:  2006-09       Impact factor: 5.223

5.  How to build a myofibril.

Authors:  Joseph W Sanger; Songman Kang; Cornelia C Siebrands; Nancy Freeman; Aiping Du; Jushuo Wang; Andrea L Stout; Jean M Sanger
Journal:  J Muscle Res Cell Motil       Date:  2005       Impact factor: 2.698

6.  microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart.

Authors:  Ning Liu; Svetlana Bezprozvannaya; Andrew H Williams; Xiaoxia Qi; James A Richardson; Rhonda Bassel-Duby; Eric N Olson
Journal:  Genes Dev       Date:  2008-11-17       Impact factor: 11.361

7.  Network reconstruction and systems analysis of cardiac myocyte hypertrophy signaling.

Authors:  Karen A Ryall; David O Holland; Kyle A Delaney; Matthew J Kraeutler; Audrey J Parker; Jeffrey J Saucerman
Journal:  J Biol Chem       Date:  2012-10-22       Impact factor: 5.157

8.  Cardiac troponin T mutations: correlation between the type of mutation and the nature of myofilament dysfunction in transgenic mice.

Authors:  D E Montgomery; J C Tardiff; M Chandra
Journal:  J Physiol       Date:  2001-10-15       Impact factor: 5.182

9.  Progenitor cell therapy in a porcine acute myocardial infarction model induces cardiac hypertrophy, mediated by paracrine secretion of cardiotrophic factors including TGFbeta1.

Authors:  Brendan Doyle; Paul Sorajja; Brian Hynes; Arun H S Kumar; Phillip A Araoz; Paul G Stalboerger; Dylan Miller; Cynthia Reed; Jeffrey Schmeckpeper; Shaohua Wang; Chunsheng Liu; Andre Terzic; David Kruger; Stephen Riederer; Noel M Caplice
Journal:  Stem Cells Dev       Date:  2008-10       Impact factor: 3.272

10.  The expression of mRNA of cytokines and of extracellular matrix proteins in triiodothyronine-treated rat hearts.

Authors:  Barbara Ziegelhöffer-Mihalovicová; Wilfried Briest; Hideo A Baba; Beate Rassler; Heinz-Gerd Zimmer
Journal:  Mol Cell Biochem       Date:  2003-05       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.